We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
CEL-SCI is a pioneer in cancer immunotherapy. We believe that boosting a patient's immune system while it is still intact should provide the greatest possible impact on survival. Consequently, in its Phase 3 clinical study CEL-SCI is treating patients who are newly diagnosed with advanced primary head and neck cancer with Multikine BEFORE they receive surgery, radiation and/or chemotherapy. The Phase 3 trial is the largest ever in head and neck cancer with 928 patients enrolled. With the last patient enrolled in the study in September 2016, final data read-out based on 298 events is expected in the near future. Multikine has received Orphan Drug designation from the FDA. Advanced primary head and neck cancer represents an unmet medical need with the last FDA approval about 60 years ago.
CEL-SCI's LEAPS technology is being developed as a therapeutic vaccine for rheumatoid arthritis and is supported by grants from the NIH. The Company has operations in Vienna, VA, and Baltimore, MD.